Previous 10 | Next 10 |
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the first quarter 20...
• Co-founder and Chief Scientist Parag Mallick, Ph.D., to present lecture at Annual Congress of the European Proteomics Association (EuPA) • Associate Director Greg Kapp, Ph.D., to present poster at American Association for Cancer Research (AACR) Annual Meeting S...
SEATTLE, March 31, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Karen Akinsanya, Ph.D., to its Board of Dir...
Nautilus Biotechnology (NASDAQ:NAUT) stock rose 5.7% after the firm disclosed that CEO and president Sujal Patel bought 50K shares at $3.57-3.60, worth ~180K. NAUT also disclosed that Patel exercised a stock option to buy 100 shares at $10/share. Following the transactions, Patel no...
Nautilus Biotechnology, Inc. (NAUT) Q4 2021 Earnings Conference Call February 24, 2022 8:30 AM ET Company Participants Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientific Officer Anna Mowry - Chief Financial Officer Conference Call Particip...
The following slide deck was published by Nautilus Biotechnology, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Nautilus Biotechnology, Inc. 2021 Q4 - Results - Earnings Call Presentation
Nautilus Biotechnology press release (NASDAQ:NAUT): Q4 GAAP EPS of -$0.13 in-line.Cash, cash equivalents, and investments were $362.1 million as of December 31, 2021. For further details see: Nautilus Biotechnology GAAP EPS of -$0.13 in-line
SEATTLE, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021. ...
Nautilus Biotechnology (NASDAQ:NAUT) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$0.14 For further details see: Nautilus Biotechnology Q4 2021 Earnings Preview
ABEV,ACIW,ACRS,AEP,AGIO,AHCO,ALIM,AMT,ATHM,OTCQX:AXAHY,AZUL,BABA,BLI,BUD,CARS,CBRE,CCO,CCOI,OTCPK:CDUAF,CGEN,CLDT,CMPS,CWT,CYD,DAO,DBRG,OTCPK:DDAIF,DEN,DISCA,DISH,DOCN,OTCQX:DTEGY,EDIT,ELAN,EME,EXPI,FOLD,GCI,GLNG,GNK,GNL,GTLS,HMHC,HYLN,IBP,IMUX,IONS,IRM,ISEE,KDP,KRP,OTCPK:LBLCF,LNG,LNTH,LXP,L...
News, Short Squeeze, Breakout and More Instantly...
Nautilus Biotechnology Inc. Company Name:
NAUT Stock Symbol:
NASDAQ Market:
Nautilus Biotechnology Inc. Website:
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. “In Q2, we saw con...
SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 3...
SEATTLE, May 23, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Goldman Sachs 45th Annual Healthcare Conference. Nauti...